Anyone experiencing severe cramping, extreme nausea, or dizziness during GLP-1 therapy should contact their provider immediately
however, when used alongside insulin or sulfonylureas in people with diabetes, the risk of low blood glucose is increased and monitoring is important
However, if youve already gone through menopause and start experiencing bleeding on your GLP-1, that is not expected and should be reported to your healthcare provider
While the safety of GLP-1 RAs is well established, current scientific evidence on the efficacy of microdosing GLP-1 RAs is lacking and further research is required to assess its benefits at lower doses
10.1021/acs.jproteome.3c00498 83 LiuJ.YangF.GaoB.YangL.CaoY.ZhouY
Researchers weighing their options should read the complete retatrutide versus semaglutide analysis for detailed mechanistic comparisons